Overview

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study (CLN-504) is to determine the safety and develop a dosing regimen of an investigational anticoagulant drug (ATI-5923) in patients with atrial fibrillation.
Phase:
Phase 2
Details
Lead Sponsor:
ARYx Therapeutics